Literature DB >> 12486986

Secondary prevention following myocardial infarction: evidence from an audit in South Wales that the National Service Framework for coronary heart disease does not address all the issues.

P Underwood1, P Beck.   

Abstract

OBJECTIVES: To assess local uptake of treatments for secondary prevention of myocardial infarction and compare with targets in the National Service Framework (NSF) for coronary heart disease.
DESIGN: Retrospective audit of case notes with follow up questionnaire at 1 year.
SETTING: Teaching hospital and community. PARTICIPANTS: 100 patients alive in December 1998 who had been admitted with an acute myocardial infarction between October 1997 and October 1998. MAIN OUTCOME MEASURES: Local use of aspirin, beta blockers, ACE inhibitors, and statins.
RESULTS: Unless contraindicated, discharge aspirin use was 100%, beta blocker use 84%, statin prescription and/or provision of dietetic advice 66% and ACE inhibitors where any heart failure was found was 97%. 1-2 years later total cholesterol remained greater than 5.0 mmol/l in 25% of patients, 24% had stopped beta blockers, and ACE inhibitors remained at a low dose in half of those surveyed.
CONCLUSIONS: The NSF for coronary heart disease states that by April 2002 80-90% of patients should be prescribed appropriate secondary prevention. This had nearly been achieved at hospital discharge in 1999. However, follow up indicated problems in ongoing care with cholesterol targets not always being achieved, beta blockers often being stopped, and ACE inhibitors frequently remaining at low doses. Gaining maximum benefit from treatment depends on these secondary targets also being achieved. In these aspects of secondary prevention the NSF represents only an initial step towards effective prevention of coronary heart disease; perhaps the most difficult and expensive steps are yet to be fully realised.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12486986      PMCID: PMC1743619          DOI: 10.1136/qhc.11.3.230

Source DB:  PubMed          Journal:  Qual Saf Health Care        ISSN: 1475-3898


  13 in total

Review 1.  Secondary prevention in acute myocardial infarction.

Authors:  R H Mehta; K A Eagle
Journal:  BMJ       Date:  1998-03-14

Review 2.  Beta-blockers for the treatment of hypertension in patients with diabetes: exploring the contraindication myth.

Authors:  S R Majumdar
Journal:  Cardiovasc Drugs Ther       Date:  1999-09       Impact factor: 3.727

3.  Patients' understandings of heart attack: implications for prevention of recurrence.

Authors:  R Wiles; A Kinmonth
Journal:  Patient Educ Couns       Date:  2001-08

4.  beta Blockade after myocardial infarction: systematic review and meta regression analysis.

Authors:  N Freemantle; J Cleland; P Young; J Mason; J Harrison
Journal:  BMJ       Date:  1999-06-26

5.  Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.

Authors:  A S Hall; G D Murray; S G Ball
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

6.  Current therapies for secondary prevention after myocardial infarction.

Authors:  C E Cannon; S C Smith
Journal:  Curr Opin Cardiol       Date:  1999-03       Impact factor: 2.161

7.  A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).

Authors:  T J Bowker; T C Clayton; J Ingham; N R McLennan; H L Hobson; S D Pyke; B Schofield; D A Wood
Journal:  Heart       Date:  1996-04       Impact factor: 5.994

8.  Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction.

Authors:  J Mason; P Young; N Freemantle; R Hobbs
Journal:  BMJ       Date:  2000-11-04

9.  Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). The SHIP Collaborative Group.

Authors:  K Jolly; F Bradley; S Sharp; H Smith; S Thompson; A L Kinmonth; D Mant
Journal:  BMJ       Date:  1999-03-13

10.  Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1995-05-20       Impact factor: 79.321

View more
  3 in total

1.  Secondary prevention of coronary heart disease in South Wales: a survey following myocardial infarction.

Authors:  P M Underwood; L S Cozma; K Laji; H Cohen; K Oboubie; P Beck
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

2.  Pursuing integration of performance measures into electronic medical records: beta-adrenergic receptor antagonist medications.

Authors:  M Weiner; T E Stump; C M Callahan; J N Lewis; C J McDonald
Journal:  Qual Saf Health Care       Date:  2005-04

3.  Overprescribing of lipid lowering agents.

Authors:  M A Smith; E D Cox; J M Bartell
Journal:  Qual Saf Health Care       Date:  2006-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.